EBV vac: New Safe Vaccine for Prevention of Epstein-Barr Virus Infections
Professor Ritter and his co-workers from the Division of Virology, University Hospital of the RWTH Aachen, created a new recombinant Epstein-Barr Virus (EBV)
which has lost the ability to enter the state of latent persistency after infecting host cells. The mutant virus only causes a self-limited infection and is unable to immortalize B-lymphocytes following Infection. Having lost the oncogenic potential of wild type EBV it fulfils the prerequisite for a live vaccine. The inventors generated a mutant virus allowing expression of lytic genes, but preventing the expression of EBV encoded genes essential for the establishment of viral latency. Mutant virus infected B-lymphocytes died after the productive phase.
Further Information: PDF
Phone: +49 (0)208/94105 0
Dipl.-Ing. Alfred Schillert
Alle Nachrichten aus der Kategorie: Technology Offerings